ArticleThe Journal of clinical investigation1995
Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.
Article in The Journal of clinical investigation, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 124 citations in OpenAlex.
- Mathematical modelling of the influence ofHeliyon · 2024Article
- COVID-19 and Cardiovascular Disease: From Bench to Bedside.Circulation research · 2021Review
- Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).Expert opinion on therapeutic patents · 2018Review
- Exercise perspective on common cardiac medications.Integrative medicine research · 2013Review
- Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?Annals of vascular surgery · 2012Review
- Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension.International journal of hypertension · 2012Article
- Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.Heart failure reviews · 2008Review
- The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure.Current cardiology reports · 2007Review
- Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.The Journal of clinical investigation · 2004Article
- The renin-angiotensin system in mitral regurgitation: a typical example of tissue activation.Current cardiology reports · 2002Review
- Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.British journal of pharmacology · 2000Article
- Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.Current cardiology reports · 2000Review
- Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.The Western journal of medicine · 1998Article
- Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.Clinical cardiology · 1997Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been proposed that the contribution of myocardial tissue angiotensin converting enzyme (ACE) to angiotensin II (Ang II) formation in the human heart is low compared with non-ACE pathways. However, little is known about the actual in vivo contribution of these pathways to Ang II formation in the human heart. To examine angiotensin II formation in the intact human heart, we administered intracoronary 123I-labeled angiotensin I (Ang I) with and without intracoronary enalaprilat to orthotopic heart transplant recipients. The fractional conversion of Ang I to Ang II, calculated after separation of angiotensin peptides by HPLC, was 0.415 +/- 0.104 (n = 5, mean +/- SD). Enalaprilat reduced fractional conversion by 89%, to a value of 0.044 +/- 0.053 (n = 4, P = 0.002). In a separate study of explanted hearts, a newly developed in vitro Ang II-forming assay was used to examine cardiac tissue ACE activity independent of circulating components. ACE activity in solubilized left ventricular membrane preparations from failing hearts was 49.6 +/- 5.3 fmol 125I-Ang II formed per minute per milligram of protein (n = 8, +/- SE), and 35.9 +/- 4.8 fmol/min/mg from nonfailing human hearts (n = 7, P = 0.08). In the presence of 1 microM enalaprilat, ACE activity was reduced by 85%, to 7.3 +/- 1.4 fmol/min/mg in the failing group and to 4.6 +/- 1.3 fmol/min/mg in the nonfailing group (P < 0.001). We conclude that the predominant pathway for angiotensin II formation in the human heart is through ACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.